Intravenous immunoglobulins in dermatology. Part 1: biological mechanisms and methods of administration
Authors:
- 1 July 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 43 (5) , 513-517
Abstract
Intravenous immunoglobulin (IVIg) is a solution of human IgG, salt, sugars and solvents, which is used to treat a multitude of diseases. Although IVIg has been known to treat many diseases safely and successfully, there are relatively few supporting randomized controlled trials. In this article, we review the biological mechanisms of IVIg in dermatological disorders and the practicalities of its use, including its mechanism of action, dosing, availability, costs and adverse effects.Keywords
This publication has 12 references indexed in Scilit:
- The Production Processes and Biological Effects of Intravenous ImmunoglobulinBiomolecules, 2016
- Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory DermatosesInternational Journal of Inflammation, 2016
- Manufacture of Immunoglobulin Products for Patients with Primary Antibody Deficiencies – The Effect of Processing Conditions on Product Safety and EfficacyFrontiers in Immunology, 2014
- Comparison of Intravenous Immunoglobulin Formulations: Product Formulary, and Cost ConsiderationsHospital Pharmacy, 2011
- A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiencyClinical and Experimental Immunology, 2007
- Intravenous Immunoglobulin: Properties, Mode of Action and Practical Use in DermatologyActa Dermato-Venereologica, 2007
- A Case of Deep Vein Thrombosis and Pulmonary Thromboembolism after Intravenous Immunoglobulin TherapyJournal of Korean Medical Science, 2007
- Venous and arterial thrombosis following administration of intravenous immunoglobulinsBlood Coagulation & Fibrinolysis, 2005
- Acute renal failure associated with immunoglobulin therapyAmerican Journal of Kidney Diseases, 1995
- Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk FactorsAnnals of Internal Medicine, 1994